February 28, 2018 / 11:18 AM / 6 months ago

BRIEF-BioCryst Announces Initiation Of APeX-S Long-Term Safety Trial Of BCX7353 In Patients With Hereditary Angioedema

Feb 28 (Reuters) - Biocryst Pharmaceuticals Inc:

* BIOCRYST ANNOUNCES INITIATION OF THE APEX-S LONG-TERM SAFETY TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below